NCT00897793

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

A Pilot Study of TGF-beta as a Potential Target for Prevention of Radiation-Induced Injury

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 25 (actual)
• Sponsor: Vanderbilt-Ingram Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Measuring levels of transforming growth factor-beta (TGF-beta) in the blood of patients with epithelial cancers (head and neck, lung, breast, colorectal, and prostate) may help doctors predict how patients will respond to treatment with radiation therapy. PURPOSE: This research study is measuring levels of TGF-beta in patients with epithelial cancers who are undergoing radiation therapy.

Detailed description

OBJECTIVES: * To determine whether there is a dose-dependent increase in TGF-beta following radiotherapy in patients with epithelial cancers. OUTLINE: Patients undergo blood sample collection prior to treatment, 24-72 hours after the first fraction of radiotherapy, and at the end of radiotherapy. Patients will also be asked for a weekly blood sample, but this is optional. Samples are analyzed to compare pre- and post-treatment TGF-beta levels.

Conditions

• Breast Cancer
• Colorectal Cancer
• Head and Neck Cancer
• Lung Cancer
• Prostate Cancer

Interventions

Type	Name	Description
PROCEDURE	venipuncture	Venipuncture for blood samples. Samples will be tested for TGF-beta.
RADIATION	radiation therapy	Radiation treatments vary according to type of cancer and by patient per doctors' recommendation

Timeline

• Start date: 2006-01-01
• Primary completion: 2010-07-01
• Completion: 2010-07-01
• First posted: 2009-05-12
• Last updated: 2013-04-12

Locations

3 sites across 1 country: United States